The Hindu and Times of India report that drugs used to treat spinal muscular atrophy (SMA) will be made available in all districts. The coverage frames this as an expansion of access for people affected by SMA, aiming to ensure treatment is not limited to select regions.
The Hindu’s headline specifies risdiplam—an SMA medicine—stating that free treatment for SMA patients is planned across all districts. Times of India delivers the same core message more generally, focusing on making SMA drugs available nationwide by district. Aside from the mention of risdiplam and the “free” framing in The Hindu, both outlets present the policy move as a broad rollout intended to improve availability.
Both stories do not provide further details in the supplied summaries, such as timelines, eligibility criteria, funding mechanisms, or the responsible government body.
